tradingkey.logo

TransCon® HGH Boosted Benefits Of TransCon® CNP In Children With Achondroplasia At Week 26

ReutersJun 9, 2025 11:06 AM

- Ascendis Pharma A/S A71.F:

  • TRANSCON® HGH BOOSTED TREATMENT BENEFITS OF TRANSCON® CNP IN CHILDREN WITH ACHONDROPLASIA AT WEEK 26 INTERIM ANALYSIS OF THE PHASE 2 COACH TRIAL

  • ASCENDIS PHARMA A/S - TRANSCON CNP-TREATED COHORT SHOWS 8.25 CM/YEAR AGV

  • ASCENDIS PHARMA A/S - COMBINATION TREATMENT SHOWS IMPROVED BODY PROPORTIONALITY AT WEEK 26

  • ASCENDIS PHARMA A/S -SAFETY AND TOLERABILITY DATA CONSISTENT WITH THOSE OBSERVED FOR TRANSCON HGH AND TRANSCON CNP MONOTHERAPIES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI